Sucralan

How often in a day do you take medicine? How many times? Once in a day Twice in a day 3 times in a day 4 times in a day

Sucralan uses

• Description
• Clinical pharmacology
• Clinical trials
• Indications and usage
• Contraindications
• Precautions
• Adverse reactions
• Overdosage
• Dosage and administration
• Sucralfate 1gm tablet
• Sucralan reviews

DESCRIPTION

Sucralan is an α-D-glucopyranoside, β-D-fructofuranosyl-, octakis(hydrogen sulfate), aluminum complex.

R = SO Al(OH) _{3 2}

Tablets for oral administration contain 1 g of Sucralan.

Structural formula for Sucralan

CLINICAL PHARMACOLOGY

Sucralan is only minimally absorbed from the gastrointestinal tract. The small amounts of the sulfated disaccharide that are absorbed are excreted primarily in the urine.

Although the mechanism of sucralfate’s ability to accelerate healing of duodenal ulcers remains to be fully defined, it is known that it exerts its effect through a local, rather than systemic, action. The following observations also appear pertinent:

• Studies in human subjects and with animal models of ulcer disease have shown that Sucralan forms an ulcer-adherent complex with proteinaceous exudate at the ulcer site.
• , a sucralfate-albumin film provides a barrier to diffusion of hydrogen ions. In vitro
• In human subjects, Sucralan given in doses recommended for ulcer therapy inhibits pepsin activity in gastric juice by 32%.
• , Sucralan absorbs bile salts. In vitro

These observations suggest that sucralfate’s antiulcer activity is the result of formation of an ulcer-adherent complex that covers the ulcer site and protects it against further attack by acid, pepsin, and bile salts. There are approximately 14 to 16 mEq of acid-neutralizing capacity per 1 g dose of Sucralan.

CLINICAL TRIALS

INDICATIONS AND USAGE

Sucralan is indicated in:

• Short-term treatment (up to 8 weeks) of active duodenal ulcer. While healing with Sucralan may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.
• Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers.

CONTRAINDICATIONS

There are no known contraindications to the use of Sucralan.

PRECAUTIONS

Duodenal ulcer is a chronic, recurrent disease. While short-term treatment with Sucralan can result in complete healing of the ulcer, a successful course of treatment with Sucralan should not be expected to alter the posthealing frequency or severity of duodenal ulceration.

Special Populations

Drug Interactions

Some studies have shown that simultaneous Sucralan administration in healthy volunteers reduced the extent of absorption of single doses of the following: cimetidine, digoxin, fluoroquinolone antibiotics, ketoconazole, l-thyroxine, phenytoin, quinidine, ranitidine, tetracycline, and theophylline. Subtherapeutic prothrombin times with concomitant warfarin and Sucralan therapy have been reported in spontaneous and published case reports. However, two clinical studies have demonstrated no change in either serum warfarin concentration or prothrombin time with the addition of Sucralan to chronic warfarin therapy.

The mechanism of these interactions appears to be nonsystemic in nature, presumably resulting from Sucralan binding to the concomitant agent in the gastrointestinal tract. In all case studies to date (cimetidine, ciprofloxacin, digoxin, norfloxacin, ofloxacin, and ranitidine), dosing the concomitant medication 2 hours before Sucralan eliminated the interaction. Because of the potential of Sucralan to alter the absorption of some drugs, Sucralan should be administered separately from other drugs when alterations in bioavailability are felt to be critical. In these cases, patients should be monitored appropriately.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Chronic oral toxicity studies of 24 months’ duration were conducted in mice and rats at doses up to 1 g/kg (12 times the human dose).

There was no evidence of drug-related tumorigenicity. A reproduction study in rats at doses up to 38 times the human dose did not reveal any indication of fertility impairment. Mutagenicity studies were not conducted.

Pregnancy

Teratogenic Effects

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Sucralan is administered to a nursing woman.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

Geriatric Use

Clinical studies of Sucralan tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. DOSAGE AND ADMINISTRATION

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. PRECAUTIONS Special Populations Chronic Renal Failure and Dialysis Patients

ADVERSE REACTIONS

Adverse reactions to Sucralan in clinical trials were minor and only rarely led to discontinuation of the drug. In studies involving over 2700 patients treated with Sucralan tablets, adverse effects were reported in 129 (4.7%).

Constipation was the most frequent complaint (2%). Other adverse effects reported in less than 0.5% of the patients are listed below by body system:

OVERDOSAGE

Due to limited experience in humans with overdosage of Sucralan, no specific treatment recommendations can be given. Acute oral toxicity studies in animals, however, using doses up to 12 g/kg body weight, could not find a lethal dose. Sucralan is only minimally absorbed from the gastrointestinal tract. Risks associated with acute overdosage should, therefore, be minimal. In rare reports describing Sucralan overdose, most patients remained asymptomatic. Those few reports where adverse events were described included symptoms of dyspepsia, abdominal pain, nausea, and vomiting.

DOSAGE AND ADMINISTRATION

Sucralan 1gm Tablet

Sucralan pharmaceutical active ingredients containing related brand and generic drugs:

• Sucralfate

Sucralan available forms, composition, doses:

• N/A

Sucralan destination | category:

• Human:
• Antacids, antireflux agents and antiulcerants
• Protectants

Sucralan Anatomical Therapeutic Chemical codes:

• A02BX02 - Sucralfate

Sucralan pharmaceutical companies:

• Horna Business Service
• Lannacher Heilmittel

References

1. Dailymed."SUCRALFATE TABLET [BRYANT RANCH PREPACK]". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).

Frequently asked Questions

Can i drive or operate heavy machine after consuming Sucralan?

Depending on the reaction of the Sucralan after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Sucralan not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.

Is Sucralan addictive or habit forming?

Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.

Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.

Review

sdrugs.com conducted a study on Sucralan, and the result of the survey is set out below. It is noteworthy that the product of the survey is based on the perception and impressions of the visitors of the website as well as the views of Sucralan consumers. We, as a result of this, advice that you do not base your therapeutic or medical decisions on this result, but rather consult your certified medical experts for their recommendations.

Visitor reports

Visitor reviews

There are no reviews yet. Be the first to write one!

Your name:  Email:  Spam protection:  < Type 26 here

The information was verified by Dr. Rachana Salvi, MD Pharmacology